Notice of Meeting, 28119 [E8-10565]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 95 / Thursday, May 15, 2008 / Notices
mstockstill on PROD1PC66 with NOTICES
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than June 9, 2008.
A. Federal Reserve Bank of Chicago
(Burl Thornton, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. Premier Bancorp of Illinois, Inc.,
Farmer City, Illinois, to retain 20.8
percent of the voting shares of F M
Bancorp, Inc., and thereby indirectly
retain voting shares of Farmers–
Merchants National Bank of Paxton,
both of Paxton, Illinois.
B. Federal Reserve Bank of San
Francisco (Kenneth Binning, Director,
Regional and Community Bank Group)
101 Market Street, San Francisco,
California 94105–1579:
1. Bank of Whitman Employee Stock
Ownership Plan, Colfax Washington, to
acquire 56 percent of the voting shares
of Whitman Bancorporation
Incorporated, Colfax, Washington, and
thereby indirectly acquire voting shares
of Bank of Whitman, Colfax,
Washington.
Board of Governors of the Federal Reserve
System, May 12, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc.E8–10859 Filed 5–14–08; 8:45 am]
BILLING CODE 6210–01–S
VerDate Aug<31>2005
16:18 May 14, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
28119
Dated: May 5, 2008.
Carolyn M. Clancy,
Director.
[FR Doc. E8–10565 Filed 5–14–08; 8:45 am]
BILLING CODE 4160–90–M
Notice of Meeting
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AHRQ), and agree to be available, to
conduct on an as needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications for the Announcement of
Availability of Funds for Grants
regarding Ambulatory Safety and
Quality Program: Improving
Management of Individuals with
Complex Healthcare Needs through
Health IT (R18) applications are to be
reviewed and discussed at this meeting.
These discussions are likely to reveal
personal information concerning
individuals associated with the
applications. This information is
exempt from mandatory disclosure
under the above-cited statutes.
SEP Meeting on: Ambulatory Safety and
Quality Program: Improving Management of
Individuals with Complex Healthcare Needs
through Health IT (R18).
Date: June 18–20, 2008 (Open on June 18
from 5 p.m. to 5:15 p.m. and closed for the
remainder of the meeting).
Place: Crowne Plaza, Conference Room
TBD, 3 Research Blvd, Rockville, Maryland
20850.
Contact Person: Anyone wishing to obtain
a roster of members, agenda or minutes of the
nonconfidential portions of this meeting
should contact Mrs. Bonnie Campbell,
Committee Management Officer, Office of
Extramural Research, Education and Priority
Populations, AHRQ, 540 Gaither Road, Room
2038, Rockville, Maryland 20850, Telephone
(301) 427–1554.
Agenda items for this meeting are subject
to change as priorities dictate.
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–E–0035 (formerly
Docket No. 2007E–0133) and [Docket No.
FDA–2007–E–0227 (formerly Docket No.
2007E–0148)]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; TYZEKA
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
TYZEKA and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submissions of
applications to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of patents
which claim that human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 73, Number 95 (Thursday, May 15, 2008)]
[Notices]
[Page 28119]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-10565]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Notice of Meeting
In accordance with section 10(d) of the Federal Advisory Committee
Act (5 U.S.C., Appendix 2), announcement is made of a Health Care
Policy and Research Special Emphasis Panel (SEP) meeting.
A Special Emphasis Panel is a group of experts in fields related to
health care research who are invited by the Agency for Healthcare
Research and Quality (AHRQ), and agree to be available, to conduct on
an as needed basis, scientific reviews of applications for AHRQ
support. Individual members of the Panel do not attend regularly-
scheduled meetings and do not serve for fixed terms or a long period of
time. Rather, they are asked to participate in particular review
meetings which require their type of expertise.
Substantial segments of the upcoming SEP meeting listed below will
be closed to the public in accordance with the Federal Advisory
Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.
552b(c)(6). Grant applications for the Announcement of Availability of
Funds for Grants regarding Ambulatory Safety and Quality Program:
Improving Management of Individuals with Complex Healthcare Needs
through Health IT (R18) applications are to be reviewed and discussed
at this meeting. These discussions are likely to reveal personal
information concerning individuals associated with the applications.
This information is exempt from mandatory disclosure under the above-
cited statutes.
SEP Meeting on: Ambulatory Safety and Quality Program: Improving
Management of Individuals with Complex Healthcare Needs through
Health IT (R18).
Date: June 18-20, 2008 (Open on June 18 from 5 p.m. to 5:15 p.m.
and closed for the remainder of the meeting).
Place: Crowne Plaza, Conference Room TBD, 3 Research Blvd,
Rockville, Maryland 20850.
Contact Person: Anyone wishing to obtain a roster of members,
agenda or minutes of the nonconfidential portions of this meeting
should contact Mrs. Bonnie Campbell, Committee Management Officer,
Office of Extramural Research, Education and Priority Populations,
AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850,
Telephone (301) 427-1554.
Agenda items for this meeting are subject to change as
priorities dictate.
Dated: May 5, 2008.
Carolyn M. Clancy,
Director.
[FR Doc. E8-10565 Filed 5-14-08; 8:45 am]
BILLING CODE 4160-90-M
